98%
921
2 minutes
20
Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor (serpin) that plays an important role in cardiovascular disorders and tumor development. The potential role of PAI-1 as a drug target has been evaluated in various animal models (e.g. mouse and rat). Sensitivity to PAI-1 inhibitory agents varied in different species. To date, absence of PAI-1 structures from species other than human hampers efforts to reveal the molecular basis for the observed species differences. Here we describe the structure of latent mouse PAI-1. Comparison with available structures of human PAI-1 reveals (1) a differential positioning of α-helix A; (2) differences in the gate region; and (3) differences in the reactive center loop position. We demonstrate that the optimal binding site of inhibitors may be dependent on the orthologs, and our results affect strategies in the rational design of a pharmacologically active PAI-1 inhibitor.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jsb.2010.03.006 | DOI Listing |
Mol Ther Methods Clin Dev
September 2025
Versiti Blood Research Institute, Milwaukee, WI 53226, USA.
Plasminogen activator inhibitor-1 (PAI-1) deficiency is a rare disorder that causes moderate to severe bleeding and cardiac fibrosis, caused by mutation in the gene and no detectable circulating PAI-1 protein. There are currently no therapies that can effectively replace PAI-1 because the protein has a short half-life. An alternative approach to using recombinant protein is to endogenously increase circulating PAI-1 levels using mRNA therapy.
View Article and Find Full Text PDFBiomed J
September 2025
Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University. Electronic address:
Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Although immune checkpoint inhibitors (ICIs), chemotherapy, and molecular targeted therapies have improved survival rates, therapeutic resistance remains a major barrier to curative outcomes. Recently, plasminogen activator inhibitor-1 (PAI-1) has been implicated in lung cancer progression and treatment resistance.
View Article and Find Full Text PDFFront Cardiovasc Med
August 2025
Department of Cardiology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
This case report presents a 43-year-old male patient with severe symptoms who was admitted due to dyspnea following physical activity, cough accompanied by fever, lower limb edema, and hemoptysis. The patient had a 20-year history of hypertension. Examinations revealed bilateral lower pulmonary artery thrombosis, a left ventricular thrombus, pulmonary infarction, and reduced left ventricular systolic function, with a lowest left ventricular ejection fraction (LVEF) of 26.
View Article and Find Full Text PDFBackground Gestational diabetes mellitus (GDM) has been increasingly associated with heightened cardiovascular and thrombotic risk. This study aimed to evaluate hemostatic and metabolic profiles in women with GDM to explore early markers of vascular dysfunction. Methods A retrospective cross-sectional study was conducted among 250 pregnant women diagnosed with GDM between December 2022 and October 2023 at multiple tertiary healthcare facilities in Pakistan.
View Article and Find Full Text PDFJ Virol
September 2025
School of Life and Environmental Sciences, The University of Sydney, Camperdown, New South Wales, Australia.
Unlabelled: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein mediates canonical cell entry via ACE2 and has also been implicated as an activator of a diverse range of signaling pathways. Here, we present evidence that the RGD (Arg-Gly-Asp) motif within the receptor-binding domain (RBD) of the S1 fragment of the S protein induces TGF-β cytokine expression. RGD peptides are well characterized as ligands for a subset of integrin complexes primarily containing α5 and αV subunits.
View Article and Find Full Text PDF